MedinGlobal

Edit Template

CELLCEPT 500MG

In Stock

CELLCEPT 500MG contains Mycophenolate mofetil 500MG and is listed as a prescription immunosuppressant associated with the prevention of rejection after certain organ transplants. It belongs to the antimetabolite class and works by reducing the proliferation of immune cells involved in transplant rejection. Treatment requires specialist supervision and appropriate monitoring, particularly for pregnancy risks, infections and changes in blood counts.

Medinglobal provides medicine information and enquiry coordination. It does not manufacture, sell or dispense medicines directly. Availability and any subsequent supply are subject to verification by an appropriately authorised independent provider and applicable regulations.

CELLCEPT 500MG – Composition, Uses and Medicine Enquiries

Product Overview

CELLCEPT 500MG is listed as a prescription product containing Mycophenolate mofetil 500MG, marketed in the source catalogue by Roche Products India Pvt Ltd.

It belongs to the immunosuppressant; antimetabolite class and may be prescribed for the prevention of rejection after certain organ transplants.

Its active ingredient reduces the proliferation of immune cells involved in transplant rejection.

The exact manufacturer pack, formulation, approved indication and administration schedule must be checked before treatment or publication. A qualified clinician should assess suitability, interactions, contraindications and monitoring requirements.

Major pregnancy risks, infections and blood count changes require close monitoring.

Composition and Strength

The supplied product information identifies the following composition:

Active Ingredient Strength
Mycophenolate mofetil 500MG

Product Name: CELLCEPT 500MG

Generic Name: Mycophenolate mofetil

Brand Name: CELLCEPT 500MG

Strength: 500MG

Listed Marketer: Roche Products India Pvt Ltd

The composition and strength should be verified against the original manufacturer-labelled packaging before publication or any medicine enquiry.

Therapeutic Category and Indication

CELLCEPT 500MG belongs to the immunosuppressant category and is classified as an antimetabolite.

It may be prescribed for the prevention of rejection after certain organ transplants.

Mycophenolate mofetil reduces the proliferation of immune cells involved in transplant rejection.

Treatment choice depends on the confirmed diagnosis, previous treatment, organ function and other medicines. The benefit-risk balance, approved use and monitoring plan must be determined by the treating specialist.

Major pregnancy risks, infections and blood count changes require close monitoring.

Administration Information

The supplied product information identifies an oral tablet taken as prescribed by the transplant team.

The tablet should be swallowed whole.

Patients should follow only the treating clinician’s instructions and the approved product label. They should not independently adjust the dose, skip safety monitoring or switch formulations without medical advice.

The exact administration schedule must be verified against the approved product information.

Product Presentation and Availability

The product enquiry can be made using the following details:

  • Product Name: CELLCEPT 500MG
  • Generic Name: Mycophenolate mofetil
  • Strength: 500MG
  • Company Name: Roche Products India Pvt Ltd
  • Therapeutic Category: Immunosuppressant
  • Medicine Class: Antimetabolite
  • Indication: Prevention of rejection after certain organ transplants
  • Administration: Oral tablet

The exact dosage form, pack size, batch, storage, expiry and product-specific presentation require verification from original manufacturer packaging and an authorised provider.

Product details and supply eligibility may vary by country. A product listing does not confirm current stock or availability.

Prescription and Patient Safety

CELLCEPT 500MG is listed as a prescription medicine and requires specialist supervision.

Treatment suitability, contraindications, interactions and monitoring requirements must be evaluated by the treating specialist.

Major pregnancy risks, infections and blood count changes require close monitoring.

Patients should follow the approved product label and their transplant team’s instructions. They should not independently change the treatment schedule or discontinue treatment.

Medicine Enquiry Coordination Through Medinglobal

Medinglobal is a healthcare coordination platform. It can receive medicine information requests and, where legally permissible, connect patients or institutions with appropriately authorised independent pharmaceutical providers.

Medinglobal does not itself sell, dispense, manufacture or export medicines.

Product availability, lawful supply, prescription validation, commercial terms and destination requirements must be verified by the independent provider. Submitting an enquiry does not guarantee fulfilment.

How to Submit a CELLCEPT 500MG Enquiry

To help identify the requested product, include the following details:

  1. Product name: CELLCEPT 500MG.
  2. Generic name: Mycophenolate mofetil.
  3. Required strength: 500MG.
  4. Required formulation and quantity.
  5. Destination country.
  6. Valid prescription or institutional documents, where required.

Medinglobal may coordinate an introduction to a suitably authorised provider. The provider independently verifies product details, regulatory eligibility and any transaction.

Frequently Asked Questions

What is CELLCEPT 500MG used for?

CELLCEPT 500MG is associated with the prevention of rejection after certain organ transplants. The treating prescriber confirms the approved use.

What is the composition of CELLCEPT 500MG?

The supplied catalogue lists Mycophenolate mofetil 500MG as its active ingredient. The composition should be verified against the original product packaging.

How is CELLCEPT 500MG administered?

The supplied information identifies an oral tablet taken as prescribed by the transplant team and swallowed whole.

Which company is listed for CELLCEPT 500MG?

Roche Products India Pvt Ltd is listed as the marketer in the supplied product information.

Does CELLCEPT 500MG require medical supervision?

Yes. Treatment requires specialist supervision and monitoring, particularly regarding pregnancy risks, infections and blood count changes.

Can Medinglobal supply CELLCEPT 500MG directly?

No. Medinglobal coordinates medicine enquiries with independent authorised providers where legally permissible.

Product Name

Generic Name

Brand Name

Composition

Strength

Therapeutic Category

Medicine Class

Indication

Dosage Form

Route of Administration

Reviews

There are no reviews yet.

Be the first to review “CELLCEPT 500MG”

Your email address will not be published. Required fields are marked *

Pharmaceutical Disclaimer

Medinglobal Platform does not sell, dispense, manufacture or prescribe medicines. Pharmaceutical information on this page is provided solely for general information, product identification and enquiry coordination. Product listing is not medical advice, a recommendation or an offer for sale by Teji Radiance or the Medinglobal Partnership Firm. Prescription medicines require a valid prescription where applicable. Any regulated pharmaceutical activity is undertaken by the relevant independent provider subject to applicable law. Always consult an appropriately qualified healthcare professional before using or changing any medicine.

Scroll to Top